144 citations
,
November 2020 in “Frontiers in immunology” This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.
October 2024 in “Stem Cell Research & Therapy” This study found that CGF may be effective in reducing inflammation and improving skin conditions in psoriasis, particularly in patients resistant to other treatments.
December 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.
February 2023 in “Research Square (Research Square)” This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.
September 2022 in “The American Journal of Dermatopathology” This study found that IL-17 expression was significantly higher in perifollicular fibrosis of active Lichen planopilaris lesions, suggesting that targeting IL-17 could impact the disease's progression.